The NHS Choices “Behind the Headlines” service produces regular critical appraisals of recent research about elderly care and dementia-related topics which have appeared in the news. Here is one more of these master-class evaluations.
Animal Research on Psoriasis Drug to Slow or Reverse Progression of Alzheimer’s Disease?
Immune system proteins IL-12 and IL-23 play a potential role in Alzheimer’s Disease, according to mouse models. Research published in Nature Medicine, based on animal research using mice, suggests that blocking these proteins with antibodies against a component called p40 could reduce the formation of amyloid beta plaque and might apparently reverse some of the associated behavioural problems in a mouse model of Alzheimer’s Disease.
NICE already recommends treatment of severe psoriasis that has not responded to standard therapy with a drug containing an antibody against p40 (ustekinumab), so there could be shorter delays before human trials. More research is required.
Psoriasis drug could hold key to dementia treatment. London: NHS Choices; Behind the Headlines, November 26th 2012.
This relates to:
Full Text Link (b) (Note: This article requires a suitable Athens password, a journal subscription or payment for access).
Vom Berg, J. Prokop, S. [and] Miller, KR. [et al] (2012). Inhibition of IL-12/IL-23 signaling reduces Alzheimer’s disease-like pathology and cognitive decline. Nature Medicine. Epub ahead of print. November 25th 2012.
[A brief reference to this item features in Dementia and Elderly Care: the Latest Evidence Newsletter (RWNHST), Volume 3 Issue 5, January 2013].